Skip to main content

Table 3 ICU management within the first 28 days following ICU admission

From: Impact of renin–angiotensin–aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study

Characteristic

ACEi/ARB n (%)

Available number

Non-ACEi/ARB n (%)

Available number

Antivirals

222 (52)

424

90 (57)

158

Antibiotics

501 (96)

522

185 (94)

196

Corticosteroids

247 (57)

437

78 (47)

167

Heparin

353 (87)

408

125 (84)

148

Prone position

290 (55)

527

93 (47)

198

Mechanical ventilation

506 (96)

528

190 (96)

198

ECMO

79 (15)

527

26 (13)

198

Inhaled nitric oxide

56 (11)

527

22 (11)

198

CRRT

89 (18)

494

38 (21)

185

Vasoactive drugs

304 (62)

487

114 (62)

184

Cardiac assist devices

34 (7)

496

11 (6)

189

Transfused RBC

108 (24)

456

46 (26)

180

Transfused platelets

18 (4)

456

5 (3)

180

Transfused plasma

23 (5)

456

11 (6)

180

  1. ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, CRRT continuous renal replacement therapies, ECMO extracorporeal membrane oxygenation